STOCK TITAN

Vanguard disaggregates holdings; Annexon (ANNX) shows 0 shares reported

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Annexon Inc: Amendment to a Schedule 13G filed by The Vanguard Group reports 0 shares beneficially owned and 0% of common stock following an internal realignment effective January 12, 2026. The amendment states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.

The filing is signed by Vanguard's Head of Global Fund Administration and lists Vanguard's Malvern, PA address; it clarifies that Vanguard and its managed accounts have the right to receive dividends or proceeds but that no single other person holds more than 5% of the class.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports zero beneficial ownership after internal reorganization.

This amendment states 0 shares and 0% beneficial ownership of Annexon Inc common stock as of the filing, citing an internal realignment on January 12, 2026 and reliance on SEC Release No. 34-39538 for disaggregated reporting.

Cash-flow treatment is not detailed in the excerpt; subsequent separate filings by Vanguard subsidiaries may disclose holdings. Future filings by those entities will provide the visible institutional ownership picture.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report for ANNX ownership in this Schedule 13G/A?

The filing reports 0 shares beneficially owned and 0% of Annexon Inc common stock. It states Vanguard will report certain subsidiaries separately after an internal realignment on January 12, 2026.

Why did The Vanguard Group change its reporting for ANNX holdings?

Vanguard states it underwent an internal realignment on January 12, 2026 and, under SEC Release No. 34-39538, certain subsidiaries will report beneficial ownership separately. The amendment reflects that disaggregation.

Does the filing say Vanguard still has rights over dividends or sale proceeds for ANNX?

The filing indicates Vanguard, including managed accounts, have the right to receive or direct receipt of dividends or proceeds for the securities reported; it also notes no other person's interest exceeds 5% of the class.

Who signed the Schedule 13G/A amendment for Vanguard?

The amendment is signed by Ashley Grim, identified as Head of Global Fund Administration, with the signature date shown as 03/26/2026.

Will this amendment change reported institutional ownership of ANNX immediately?

The amendment records disaggregated reporting by Vanguard entities and shows 0 shares for The Vanguard Group; ownership disclosures for subsidiary entities will appear in their separate filings, which will update the visible institutional ownership picture.
Annexon, Inc.

NASDAQ:ANNX

View ANNX Stock Overview

ANNX Rankings

ANNX Latest News

ANNX Latest SEC Filings

ANNX Stock Data

782.54M
133.88M
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE